Yonsei Med J.  2011 May;52(3):535-538. 10.3349/ymj.2011.52.3.535.

In Vitro Antifungal Activity of Epigallocatechin 3-O-Gallate against Clinical Isolates of Dermatophytes

• Park BJ
• Taguchi H
• Kamei K
• Matsuzawa
• Hyon SH
• Park JC

• KMID: 1777029
• DOI: http://doi.org/10.3349/ymj.2011.52.3.535

Abstract

Previously, we reported that epigallocatechin 3-O-gallate (EGCg) has growth-inhibitory effect on clinical isolates of Candida species. In this study, we investigated the antifungal activity of EGCg and antifungal agents against thirty-five of dermatophytes clinically isolated by the international guidelines (M38-A2). All isolates exhibited good susceptibility to EGCg (MIC50, 2-4 microg/mL, MIC90, 4-8 microg/mL, and geometric mean (GM) MICs, 3.36-4 microg/mL) than those of fluconazole (MIC50, 2-16 microg/mL, MIC90, 4-32 microg/mL, and GM MICs, 3.45-25.8 microg/mL) and flucytosin (MIC50, MIC90, and GM MICs, >64 microg/mL), although they were less susceptible to other antifungal agents, such as amphotericin B, itraconazole, and miconazole. These activities of EGCg were approximately 4-fold higher than those of fluconazole, and were 4 to 16-fold higher than flucytosin. This result indicates that EGCg can inhibit pathogenic dermatophyte species. Therefore, we suggest that EGCg may be effectively used solely as a possible agent or combined with other antifungal agents for antifungal therapy in dermatophytosis.

Keyword

Epigallocatechin 3-O-gallate; Dermatophytes; Microsporum canis; Trichophyton mentagrophytes; Trichophyton rubrum; Susceptibility

MeSH Terms

Antifungal Agents/*pharmacology
Arthrodermataceae/*drug effects/isolation & purification
Catechin/*analogs & derivatives/pharmacology
Microbial Sensitivity Tests

Reference

1. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev. 1995. 8:240–259.

2. Das S, Goyal R, Bhattacharya SN. Laboratory-based epidemiological study of superficial fungal infections. J Dermatol. 2007. 34:248–253.

3. Ginter-Hanselmayer G, Weger W, Ilkit M, Smolle J. Epidemiology of tinea capitis in Europe: current state and changing patterns. Mycoses. 2007. 50:Suppl 2. 6–13.

4. Hernández-Salazar A, Carbajal-Pruneda P, Fernández Martínez R, Arenas R. [Dermatophytosis due to Trichophyton rubrum. Ten-year period (1996-2006) data collection in Dermatology Department in Mexico City]. Rev Iberoam Micol. 2007. 24:122–124.

5. Porro AM, Yoshioka MC, Kaminski SK, Palmeira Mdo C, Fischman O, Alchorne MM. Disseminated dermatophytosis caused by Microsporum gypseum in two patients with the acquired immunodeficiency syndrome. Mycopathologia. 1997. 137:9–12.

6. Seyfarth F, Ziemer M, Gräser Y, Elsner P, Hipler UC. Widespread tinea corporis caused by Trichophyton rubrum with non-typical cultural characteristies--diagnosis via PCR. Mycoses. 2007. 50:Suppl 2. 26–30.

7. Sarifakioglu E, Seçkin D, Demirbilek M, Can F. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. Clin Exp Dermatol. 2007. 32:675–679.

8. Robert R, Pihet M. Conventional methods for the diagnosis of dermatophytosis. Mycopathologia. 2008. 166:295–306.

9. Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008. 166:369–383.

10. Mondello F, De Bernardis F, Girolamo A, Salvatore G, Cassone A. In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts. J Antimicrob Chemother. 2003. 51:1223–1229.

11. Donia M, Hamann MT. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis. 2003. 3:338–348.

12. Lavermicocca P, Valerio F, Visconti A. Antifungal activity of phenyllactic acid against molds isolated from bakery products. Appl Environ Microbiol. 2003. 69:634–640.

13. Gertsch J, Tobler RT, Brun R, Sticher O, Heilmann J. Antifungal, antiprotozoal, cytotoxic and piscicidal properties of Justicidin B and a new arylnaphthalide lignan from Phyllanthus piscatorum. Planta Med. 2003. 69:420–424.

14. Hellio C, Pons AM, Beaupoil C, Bourgougnon N, Gal YL. Antibacterial, antifungal and cytotoxic activities of extracts from fish epidermis and epidermal mucus. Int J Antimicrob Agents. 2002. 20:214–219.

15. Sakanaka S, Kim MJ, Taniguchi M, Yamamoto T. Antibacterial substances in Japanese green tea extract against Streptococcus mutans, a cariogenic bacterium. Agric Biol Chem. 1989. 53:2307–2311.

16. Hirasawa M, Takada K, Makimura M, Otake S. Improvement of periodontal status by green tea catechin using a local delivery system: a clinical pilot study. J Periodontal Res. 2002. 37:433–438.

17. Ahn YJ, Sakanaka S, Kim MJ, Kawamura T, Fujisawa T, Mitsuoka T. Effect of green tea extract on growth of intestinal bacteria. Microb Ecol Health Dis. 1990. 3:335–338.

18. Hara Y, Ishigami T. Antibacterial activities of tea polyphenols against foodborne pathogenic bacteria. J Jpn Soc Food Sci Tech. 1989. 36:996–999.

19. Okubo S, Ikigai H, Toda M, Shimanura T. The anti-haemolysin activity of tea and coffee. Lett Appl Microbiol. 1989. 9:65–66.

20. Nakane H, Ono K. Differential inhibitory effects of some catechin derivatives on the activities of human immunodeficiency virus reverse transcriptase and cellular deoxyribonucleic and ribonucleic acid polymerases. Biochemistry. 1990. 29:2841–2845.

21. Blanco AR, La Terra Mule S, Babini G, Garbisa S, Enea V, Rusciano D. (-)Epigallo-catechin-3-gallate inhibits gelatinase activity of some bacterial isolates from ocular infection, and limits their invasion through gelatine. Biochim Biophys Acta. 2003. 1620:273–281.

22. Sudano Roccaro A, Blanco AR, Giuliano F, Rusciano D, Enea V. Epigallocatechin-gallate enhances the activity of tetracycline in staphylococci by inhibiting its efflux from bacterial cells. Antimicrob Agents Chemother. 2004. 48:1968–1973.

23. Okubo S, Toda M, Hara Y, Shimamura T. [Antifungal and fungicidal activities of tea extract and catechin against Trichophyton]. Nippon Saikingaku Zasshi. 1991. 46:509–514.

24. Park BJ, Park JC, Taguchi H, Fukushima K, Hyon SH, Takatori K. Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. Biochem Biophys Res Commun. 2006. 347:401–405.

25. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; Approved standard-second edition, CLSI document. 2008. Wayne, PA, USA: CLSI/NCCLS;M38-A2.

26. Tejasvi T, Sharma VK, Sethuraman G, Singh MK, Xess I. Invasive dermatophytosis with lymph node involvement in an immunocompetent patient. Clin Exp Dermatol. 2005. 30:506–508.

27. Zapata Garrido AJ, Romo AC, Padilla FB. Terbinafine hepatotoxicity. A case report and review of literature. Ann Hepatol. 2003. 2:47–51.

28. Huang DB, Ostrosky-Zeichner L, Wu JJ, Pang KR, Tyring SK. Therapy of common superficial fungal infections. Dermatol Ther. 2004. 17:517–522.

29. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr. 2003. 43:89–143.

30. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta. 2002. 1542:149–159.

31. Stapleton PD, Taylor PW. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci Prog. 2002. 85:57–72.

32. Hirasawa M, Takada K. Multiple effects of green tea catechin on the antifungal activity of antimycotics against Candida albicans. J Antimicrob Chemother. 2004. 53:225–229.